Why CJC-1295, Ipamorelin, Sermorelin and Tesamorelin aren't interchangeable.
Growth-hormone research uses two distinct compound families that get lumped together as "GH peptides." Understanding the difference changes how a protocol is designed.
These mimic growth hormone-releasing hormone, signalling at the GHRH receptor on the pituitary.
The GHRH (1-29) fragment — the shortest sequence retaining activity. Frequently used as a reference compound. View Sermorelin →
The clearest illustration of design intent in this category. With DAC, the half-life extends dramatically and research examines sustained signalling. Without DAC (Mod GRF 1-29), the compound is studied for short, pulsatile signalling closer to natural release patterns.
One of the few GHRH analogs to undergo extensive clinical study, researched notably for visceral adipose tissue models. View Tesamorelin →
Acts at an entirely different receptor — the ghrelin receptor (GHS-R). Its research profile is defined by selectivity: studies examine GH-axis signalling with minimal off-target activity at cortisol and prolactin pathways, unlike earlier, less selective secretagogues. View Ipamorelin →
Because the two families act on different receptors, they're frequently studied in combination — a GHRH analog and a ghrelin agonist engaging the axis from two directions. Researchers also weigh sustained versus pulsatile signalling, which is why both CJC variants remain in demand.
All compounds discussed are supplied for laboratory research use only.
Explore GH research compounds →